850
Participants
Start Date
July 25, 2022
Primary Completion Date
December 30, 2026
Study Completion Date
June 30, 2027
Tebentafusp
Tebentafusp supplied as concentrate for solution for infusion and diluted prior to administration. 0.2 mg/mL drug product will be provided as a sterile, refrigerated solution in glass vials.
Cambridge University Hospitals NHS Foundation Trust (Screening only), Cambridge
The Beatson West of Scotland Cancer Centre, Glasgow
The Clatterbridge Cancer Centre, Liverpool
University College London Hospital, London
The Christie Hospital, Manchester
Mount Vernon Cancer Centre, Middlesex
Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle
Sheffield Teaching Hospitals NHS Foundation Trust (Screening only), Sheffield
University Hospital Southampton NHS Foundation Trust, Southampton
Churchill Hospital, Oxford University Hospitals NHS Trust, Oxford
Collaborators (1)
Immunocore Ltd
INDUSTRY
University of Oxford
OTHER